Anixa Biosciences, Inc. (ANIX) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $5.83 (low: $3.50, high: $10.00), representing an upside of 102.4% from the current price $2.88.
Analysts estimate Earnings Per Share (EPS) of $-0.40 and revenue of $0.15B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.39 vs est $-0.40 (beat +1.3%). 2025: actual $-0.34 vs est $-0.36 (beat +4.4%). Analyst accuracy: 97%.
ANIX Stock — 12-Month Price Forecast
$5.83
▲ +102.43% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Anixa Biosciences, Inc., the average price target is $5.83, with a high forecast of $10.00, and a low forecast of $3.50.
The average price target represents a +102.43% change from the last price of $2.88.
Highest Price Target
$10.00
Average Price Target
$5.83
Lowest Price Target
$3.50
ANIX Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Anixa Biosciences, Inc. in the past 3 months
EPS Estimates — ANIX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.39
vs Est –$0.40
▲ 1.3% off
2025
Actual –$0.34
vs Est –$0.36
▲ 4.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ANIX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
